Molecular Testing: Key Takeaways on Next Generation Sequencing in NSCLC
May 15th 2024Medical experts explore the advantages and disadvantages of next-generation sequencing testing, highlighting the disparities in the quantity of tissue samples being sent for analysis, which can lead to inconclusive results when insufficient sample sizes are provided.
Adverse Effect Management for CAR T-Cell Therapy and Bispecifics in R/R MM
May 13th 2024In a discussion with the Oncology Brothers on the treatment of patients with relapsed/refractory multiple myeloma, Samer Al'Hadidi, MD, discusses adverse effects associated with CAR T-cell therapy and bispecific antibodies.
Patient Case 4: 50-Year-Old Woman Non-Smoker with Pleural Metastases
May 8th 2024Estelamari Rodriguez, MD, MPH, presents a case of a 50-year-old African American woman, non-smoker, with pleural metastases; the panel discusses interstitial lung disease management, the use of antibody-drug conjugates, disease timing, and strategies for providing symptomatic relief, specifically considering drug holds if steroids only offer partial relief.
Patient Case 3: A 34-Year-Old Non-Smoker with Stage IIIA NSCLC
May 8th 2024Christine Bestvina, MD, presents a case of a 34-year-old non-smoker diagnosed with Stage IIIA NSCLC after presenting with chest wall pain; the panel then explores their approaches to managing toxicities, including rashes and sores, by employing dose reductions and steroids to control adverse reactions.